| Perpetual Ethical SRI Fund (Managed Fund) (GIVE) |
Financials |
$13 |
Quarterly Portfolio Disclosure - June 2025
|
29 Aug 2025 9:41AM |
$3.210 |
$2.770 |
fallen by
13.71%
|
|
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$89 |
FY25 Appendix 4E Preliminary Final Report
|
29 Aug 2025 9:39AM |
$0.165 |
$0.100 |
fallen by
39.39%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Bubs Australia Limited reported a profit of AUD 5.54 million for the financial year ending 30 June 2025.
- Total comprehensive income for FY25 was AUD 5.17 million, accounting for other comprehensive loss.
- Net cash from operating activities was positive at AUD 6.13 million, a significant improvement from the previous year's outflow.
- Issued capital remained unchanged at AUD 356.76 million as of 30 June 2025.
- The company focused on improving cash flow and reducing liabilities, with total liabilities dropping significantly from AUD 29.88 million to AUD 14.69 million.
- Share-based payments were utilized, with a reserve increase from AUD 12.26 million to AUD 12.69 million.
- The net assets of the company increased from AUD 36.87 million to AUD 42.48 million.
- Foreign currency translation reserve showed a loss, highlighting some impact from currency fluctuations.
- Receipts from customers rose to AUD 103.75 million, indicating increased sales and market activity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flynn Gold Limited (FG1) ORDINARY FULLY PAID |
Materials |
$15 |
$130,000 in Grant Funding for Drilling at Mangana and Henty
|
29 Aug 2025 9:39AM |
$0.027 |
$0.025 |
fallen by
7.41%
|
|
FG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Flynn Gold Limited (ASX: FG1) secured $130,000 in grant funding from the Tasmanian Government's Exploration Drilling Grant Initiative (EDGI).
- The funding is aimed at supporting drill testing at the Mangana Project and the Henty South Project in Tasmania.
- Mangana Project involves drilling two diamond drill holes totaling 400 meters beneath the historic Golden Entrance mine.
- Henty South Project includes a plan to drill one 500-meter diamond hole targeting a coincident gravity and IP anomaly.
- The Mangana Project targets high-grade gold beneath historic workings that have not been drill tested for a century.
- The EDGI program is a Tasmanian State Government initiative to stimulate greenfield exploration.
- The Mangana Goldfield produced approximately 6,700 ounces of gold from 1852 to 1910.
- The Golden Entrance mine was historically the richest producer in the Mangana Goldfield.
- Preparatory activities for drilling at both projects are currently underway.
- Flynn Gold owns and controls the exploration licenses through its subsidiary, Kingfisher Exploration Pty Ltd.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dorsavi Ltd (DVL) ORDINARY FULLY PAID |
Health Care |
$36 |
DVL June 2025 Appendix 4E
|
29 Aug 2025 9:38AM |
$0.047 |
$0.030 |
fallen by
36.17%
|
|
DVL - Price-sensitive ASX Announcement
Full Release
Key Points
- DorsaVi Limited reported a loss after tax of $1,517,753 for the year ending 30 June 2025.
- Total comprehensive loss for the year was $1,542,059.
- The company raised $3,169,615 through equity contributions.
- Revenues from contracts with customers were $1,129,493.
- Cash and cash equivalents at year-end were $2,293,549.
- No dividends were declared in the financial year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dorsavi Ltd (DVL) ORDINARY FULLY PAID |
Health Care |
$36 |
DVL June 2025 Appendix 4E
|
29 Aug 2025 9:38AM |
$0.047 |
$0.030 |
fallen by
36.17%
|
|
DVL - Price-sensitive ASX Announcement
Full Release
Key Points
- DorsaVi Limited is a listed public company based in Melbourne, Australia.
- The preliminary final report is presented in Australian dollars.
- Revenue from contracts with customers for 2025 was $1,129,493, a decrease from $1,304,238 in 2024.
- The company reported a loss after income tax benefit of $1,517,753 for the year ended 30 June 2025.
- Total comprehensive income for the year was negative $1,542,059.
- Total equity at 30 June 2025 was $2,835,656, compared to $1,023,350 at 30 June 2024.
- Cash and cash equivalents increased to $2,293,549 by the end of the financial year.
- There were no dividends paid or declared during the financial year.
- On 4 July 2025, the company issued 70,000,000 shares raising $910,000 before transaction costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hubify Limited (HFY) ORDINARY FULLY PAID |
Communication Services |
$8 |
Appendix 4G & Corporate Governance Statement
|
29 Aug 2025 9:38AM |
$0.008 |
$0.015 |
risen by
87.50%
|
|
| Caprice Resources Limited (CRS) ORDINARY FULLY PAID |
Materials |
$65 |
Cleansing Notice
|
29 Aug 2025 9:37AM |
$0.088 |
$0.076 |
fallen by
13.64%
|
|
| Aspen Group (APZ) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,109 |
Proposed issue of securities - APZ
|
29 Aug 2025 9:37AM |
$4.320 |
$4.870 |
risen by
12.73%
|
|
| Magnum Mining and Exploration Limited (MGU) ORDINARY FULLY PAID |
Materials |
$22 |
HIGH-GRADE RARE EARTH LEACH TESTING BEGINS
|
29 Aug 2025 9:37AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
MGU - Price-sensitive ASX Announcement
Full Release
Key Points
- Leach testing of high-grade samples from Palmares REE Project has commenced.
- Palmares REE Project spans 18 tenements covering ~348km² in Bahia State, Brazil.
- Trench assays at Feirinha Prospect returned up to 1.69% TREO.
- Rock chip assays showed up to 1.31% TREO, enriched in Nd and Pr.
- G2 pegmatites are the main host rocks with consistent high-grade mineralization.
- 15 samples dispatched to ALS Laboratories for leach testing.
- Palmares is positioned within a region with district-scale potential for REE.
- Magnum is one of the largest landholders for REE in the region.
- Leach testing results expected by September end.
- Potential for Palmares as a significant REE project, pending testing results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$10 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.069 |
$0.032 |
fallen by
53.62%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 global sales revenue of A$7.3 million, up 49% from the prior year.
- North American Travelan® sales reached A$2.0 million, a 76% increase.
- Profit from hyperimmune products remained A$1.35 million.
- Increased selling and marketing investment by A$1.4 million.
- Focus on oral immunotherapeutics for gut-mediated diseases.
- Anticipates FDA Phase 2 meeting for Travelan® and IND approval for IMM-529 by end 2025.
- Australian launch of ProIBS planned for Q1 2026.
- Continued quarter-on-quarter growth of Travelan®.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$10 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.069 |
$0.032 |
fallen by
53.62%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 Global Sales Revenue was A$7.3 million, up 49% from the previous year.
- North American Travelan® sales increased by 76% to A$2.0 million.
- Profit from Hyperimmune products remained A$1.35 million, consistent with FY24.
- Increased investment in selling and marketing by A$1.4 million.
- Launch of ProIBS in Australia is scheduled for Q1 CY2026.
- Travelan® IMM-124E: Scheduled End of Phase 2 FDA meeting in 1H 2026.
- Anticipated FDA approval of IMM-529 (CDI) IND in December 2025.
- Immuron is a biopharmaceutical company focused on oral immunotherapeutics for gut mediated diseases.
- Cash & Term Deposit as of 30 June 2025 stood at A$5.9 million, excluding A$2.8 million raised from US placement in July 2025.
- Major shareholders include BNY Mellon Asset Management with 42.29% ownership.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$24 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.098 |
$0.083 |
fallen by
15.31%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue was $172.0 million, a 1% decrease from the prior period.
- EBITDA was reported at $12.0 million, in line with guidance.
- Normalised EBITDA increased by 4.8% to $19.5 million.
- Net Loss After Tax was $5.2 million compared to a minor loss last year.
- Revenue growth in Australia/New Zealand driven by Bunnings and grain storage.
- Revenue in developing markets increased by 14.4%.
- Challenges faced in the Americas due to tariffs and weak consumer confidence.
- Non-recurring costs included $5.4 million from D365 implementation and executive changes.
- Focus on market development and cost reduction, especially in the US and emerging markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$24 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.098 |
$0.083 |
fallen by
15.31%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue at $172 million, down 1% from prior year.
- EBITDA was $12 million, consistent with guidance.
- Net loss after tax was $5.2 million.
- Australian and New Zealand markets showed 7.6% revenue increase.
- Americas revenue declined by 11.3%, affected by tariffs and consumer sentiment.
- Developing markets like the Middle East, Europe, and Asia showed growth.
- Significant non-recurring costs impacted profitability.
- Plans to reset US operations and diversify manufacturing to reduce tariff impact.
- Expansion focus on the Middle East and Asia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$24 |
FY25 Results Announcement
|
29 Aug 2025 9:35AM |
$0.098 |
$0.083 |
fallen by
15.31%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- GALE Pacific Limited faced geopolitical and tariff challenges in FY25.
- Revenue decreased by 1.2% to $172 million.
- EBITDA declined by 15.5% to $12 million, with a net loss of $5.2 million.
- Americas revenue fell by 11.3%, impacted by consumer confidence and tariffs.
- Australia/New Zealand revenue grew 7.6% due to strong summer sales.
- Developing markets saw a 14.4% revenue increase from Middle East and Europe projects.
- Non-recurring costs totaled $5.4 million due to ERP and leadership transitions.
- FX expenses impacted profits by $2.1 million due to currency movements.
- Focus on streamlining U.S. operations and diversifying manufacturing for future growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$24 |
FY25 Results Announcement
|
29 Aug 2025 9:35AM |
$0.098 |
$0.083 |
fallen by
15.31%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- GALE Pacific faced geopolitical and tariff-related challenges in the US.
- Revenue decreased by 1.2% in FY25.
- Net loss after tax was reported at AUD 5.2 million.
- Revenue grew by 7.6% in Australia/New Zealand.
- Revenue increased by 14.4% in developing markets.
- GALE Pacific aims to restructure US operations and diversify manufacturing footprint in FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$25 |
Atomo Investor Webinar Presentation
|
29 Aug 2025 9:35AM |
$0.018 |
$0.028 |
risen by
55.56%
|
|
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
- |
Board changes to align with current scale
|
29 Aug 2025 9:35AM |
$0.056 |
$0.022 |
fallen by
60.71%
|
|
| Constellation Technologies Limited (CT1) ORDINARY FULLY PAID |
Information Technology |
$4 |
Appendix 4G
|
29 Aug 2025 9:35AM |
$0.002 |
$0.003 |
risen by
50%
|
|
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$10 |
Appendix 4E Preliminary Final Report
|
29 Aug 2025 9:35AM |
$0.069 |
$0.032 |
fallen by
53.62%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- Comprehensive loss after tax of $5,253,209 for the year ended 30 June 2025.
- Revenue from contracts with customers increased to $7,287,002.
- Net assets decreased to $8,031,833 from $12,709,444 in the previous year.
- Significant decrease in cash and cash equivalents to $2,830,526.
- Share capital increased to $88,872,756 due to share issues.
- Continued issuance of options and performance rights to key personnel.
- Post-year-end capital raising through At The Market facility in July 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$10 |
Appendix 4E Preliminary Final Report
|
29 Aug 2025 9:35AM |
$0.069 |
$0.032 |
fallen by
53.62%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 48.6% to $7,287,002.
- Loss after tax reduced by 24.3% to $5,253,209.
- Research and development expenses of $3,597,296.
- Cash position decreased to $2,830,526.
- No dividends paid or declared for the current or previous financial year.
- Continued strong sales of Travelan® in Australia and North America.
- 23.6% interest in Ateria Health Limited.
- Detailed audited financial statements expected by 30 September 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flexiroam Limited (FRX) ORDINARY FULLY PAID |
Communication Services |
$30 |
Corporate Governance Statement and Appendix 4G
|
29 Aug 2025 9:34AM |
$0.006 |
$0.020 |
risen by
233.33%
|
|
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$24 |
FY 25 Appendix 4G and Corporate Governance Statement
|
29 Aug 2025 9:34AM |
$0.098 |
$0.083 |
fallen by
15.31%
|
|
| Finexia Financial Group Limited (FNX) ORDINARY FULLY PAID |
Financials |
$11 |
Suspension from Quotation
|
29 Aug 2025 9:34AM |
$0.145 |
$0.180 |
risen by
24.14%
|
|
FNX - Price-sensitive ASX Announcement
Full Release
Key Points
- The securities of Finexia Financial Group Limited will be suspended from quotation immediately.
- The suspension is under Listing Rule 17.3.4.
- Suspension is pending the release of an announcement related to media speculation and a potential material acquisition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$25 |
2025 Appendix 4G and Corporate Governance Statement
|
29 Aug 2025 9:34AM |
$0.018 |
$0.028 |
risen by
55.56%
|
|
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$24 |
FY25 Annual Report
|
29 Aug 2025 9:34AM |
$0.098 |
$0.083 |
fallen by
15.31%
|
|
Call 1300 880 160
Start a chat
Schedule a call
